EASL 2011: First Sustained Response Data for HCV Polymerase Inhibitor Mericitabine
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 14:14
- Written by Liz Highleyman
76% of treatment-naive genotype 1 or 4 hepatitis C patients achieved 12-week sustained response to mericitabine (formerly RG7128) plus pegylated interferon/ribavirin, according to a report at EASL 2011. 
EASL 2011: Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 05 April 2011 08:05
- Written by Liz Highleyman
Almost all treatment-naive hepatitis C patients treated with Pharmasset's candidate PSI-7977 plus pegylated interferon/ribavirin experienced 12-week sustained response, and more than 90% treated with a PSI-7977 + PSI-938 all-oral combo had undetectable HCV at 14 days, researchers reported at EASL. 
Telaprevir Combo Works for HCV Patients with Prior Unsuccessful Treatment
- Details
- Category: HIV Treatment
- Published on Thursday, 31 March 2011 21:53
- Written by Vertex
The REALIZE study showed that adding telaprevir to standard hepatitis C therapy increased sustained response rates for people with previous unsuccessful treatment attempts, researchers reported this week at EASL 2011.
EASL 2011: Telaprevir Improves HCV Cure Rates Regardless of IL28B Status
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 05 April 2011 06:57
- Written by Vertex Pharmaceuticals
The Vertex experimental protease inhibitor telaprevir, taken with pegylated interferon plus ribavirin, increased sustained response in people with all IL28B gene patterns, researchers reported at EASL 2011.
Web Design and Development by